Please login to the form below
Merck says Afferent’s chronic cough drug clears mid-stage trial
MK-7264 reduces coughs per hour by 37%
Ionis says rare disease drug works, but safety concerns linger
Inotersen has been linked to cases of thrombocytopenia
Biogen hands out $120m upfront for Remedy stroke drug
Cirara vying to be first new treatment since the 1990s
Lilly set to head to regulators with CGRP migraine drug
Gathers three positive late-stage trials of galcanezumab as it chases Amgen
AZ buoyed by Imfinzi lung cancer trial
Phase III study shows PD-L1 inhibitor increased progression-free survival
GSK's Nucala posts mixed results in COPD
Conflicting late-stage trials throw doubt on its prospects
INC Research to merge with InVentiv Health
Combined will be second-largest outsourcing provider after QuintilesIMS
AZ trial adds to pessimism about anti-IL-13 asthma drugs
Firm's IL-13 inhibitor failed to reduce the number of asthma attacks compared to placebo
Tecentriq bladder cancer approval in doubt after trial failure
The PD-L1 inhibitor failed to extend overall survival in a phase III study
Riding the wave of digital disruption
The challenges and rewards of meeting consumer expectations
-
Real-world evidenceCompanies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future
-
The future of biotechWhat impact will the sector, and its R&D performance, have on pharma?
-
Sanofi agrees €250m diabetes deal with AI firm ExscientiaThe French pharma giant will pay royalties and contribute research funding
-
Teva drops laquinimod for most common form of MS after failed trialCONCERTO study showed no disability progression improvements over placebo
-
BMS claims a win in mid-stage NASH trialIts new liver disease therapy reduces fatty deposits and improves blood lipid profiles
-
AbbVie's PARP inhibitor veliparib fails to deliver Phase III trials show no increase in clinical benefit
-
Circassia exits allergy R&D after placebo effect strikes againAbandons phase IIb trial of house dust mite allergy candidate
-
Microbiome specialist Rebiotix chalks up C. diff trial successDrug therapy can prevent recurrent infections
-
Neurocrine bags FDA approval for first tardive dyskinesia drugIngrezza edges ahead of Teva’s rival drug Austedo
-
GW Pharmaceuticals strengthens research and development teamAppoints Dr Volker Knappertz and Professor Ben Whalley
-
Kymab appoints its first chief medical officerDr Sonia Quaratino joins the firm from Novartis
-
Ipsen appoints executive vice presidentAlexandre Lebeaut also set to be chief scientific officer
-
Ironwood Pharmaceuticals appoints chief development officerDr Christopher Wright joins from Axcella Health
-
Flex Pharma appoints new R&D presidentWilliam McVicar joins from Inotek
Latest research appointments
Featured jobs
- Senior Account Manager/ Account Director, Medical Communications...
-
Excellent package
- Account Director, Digital Healthcare Communications Agency
-
£45, 000 – £55, 000 benefits
- Account Director, Medical Communications
-
£60, 000 – £65, 000 benefits
- Pharmaceutical Associate Director, PR
-
£85, 000 - £100, 000 generous package
-
Director, Scientific Services
-
£80 – 90, 000 benefits
- Editorial Teal Leader, Medical Communications, London
-
Excellent package
- FREELANCE ACCOUNT DIRECTOR - MED ED OR HEALTHCARE PR - LONDON - ...
-
SUPERB DAY RATE AVAILABLE
- Senior Medical Writer, Medical Communications, London
-
Excellent package
- Account Director, Healthcare Communications
-
£50, 000 - £60, 000
- Programme Director - Healthcare PR - London
-
Salary TBC
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
Subscribe to our email news alerts
- Novartis' Swiss head of operations reveals job cuts
- Otsuka refiles 'digital' medicine for mental illness
- Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog
- Sanofi/Regeneron's Sarilumab cleared by FDA on second attempt
- Keytruda is first FDA-approved drug for molecular indication
- MSD probed by UK for blocking Remicade biosimilars
- Cactus Medical Communication Services
- Digital storytelling means building the story around data
- Pfizer gets FDA panel recommendation for biosimilar EPO
- Biogen spin-out makes first acquisition
- Pharma and free medicines: a different perspective
- TVF Communications shortlisted for the second year in a row for Writing Excellence award at Communique 2017
PMHub
Pulsar
THE SCIENCE BEHIND CREATIVE RESULTS When science meets art there's chemistry. We simply add passion, positivity and a human warmth....
Latest intelligence
- Digital storytelling means building the story around data
- The value of digital storytelling in pharma lies in its ability to convert facts and figures into compelling content for patients and HCPs....
- Pharma and free medicines: a different perspective
- Pfizer have recently announced that they will provide the breast cancer drug, palbociclib, free of charge to patients....
- The false economy of following the leader
- How can companies in the sector shake things up?...
Quick links
Infographics
